Scottish medical device company Nebu-Flow, a University of Glasgow spinout, has secured £4.7 million of investment to accelerate what it describes as the “next generation” of inhaled drugs for patients with respiratory disorders.
Noting such disorders are “the main cause of death and disability worldwide”, Nebu-Flow said: “The company’s nebuliser platform has been developed to provide a number of advantages over existing technologies.”
It observed that, overall, the worldwide inhalable drug market was valued at around 33 billion dollars in 2023, with the nebuliser market valued at in excess of one billion dollars. The funding round was led by SCVC, a UK-based venture capital firm that invests in early-stage, “deep-tech” spinouts. It was supported by economic development agency Scottish Enterprise, Foresight WAE Technology, SIS Ventures, Ascension, and Conduit EIS Impact Fund.
READ MORE: Ian McConnell: Toxic Tory ideology and all the wrong priorities
Elijah Nazarzadeh, chief executive and co-founder of Nebu-Flow, said: “Essentially, our technology provides new opportunities for targeted drug delivery to the lungs as well as drug delivery to the cardiovascular and central nervous systems. We are engaged with a number of partners in the UK and North America who are currently trialling the product as we prepare for the regulatory approval stage.”
He added: “Our mission is to revolutionise respiratory drug delivery. The investment accelerates our development activities to position the company for inhalation delivery of RNA-based formulations. We now look forward to the final product development and commercialisation stages, with the support of SCVC and our other investors."
READ MORE: Ian McConnell: Bizarre Brexit view of a true believer
Harry Destecroix, managing partner of SCVC, said: “We are deeply impressed by the team's achievement of its technical and commercial milestones to date, demonstrating their capability and readiness for the next phase in healthcare innovation. This investment underscores our confidence in Nebu-Flow’s groundbreaking nebulisation technology, which is poised to transform respiratory drug delivery, improve health and deliver impact."
READ MORE: Ian McConnell: Next First Minister faces huge challenge
Kerry Sharp, director of entrepreneurship and investment at taxpayer-backed Scottish Enterprise, said: “Scottish Enterprise has supported Nebu-Flow’s ambition to revolutionise respiratory drug delivery over a number of years, from inclusion in our ‘unlocking ambition’ entrepreneurship programme and feasibility grant support all the way through to this investment, which has in turn helped unlock access to other large grant awards for the company.”
She added: “The human health sector is a key opportunity area for growth in Scotland, with our academic capability already delivering world-class successes in the field. Companies like Nebu-Flow can play a vital role in transforming our economy by scaling up, creating high-value jobs and competing internationally. It has been fantastic to follow their journey from university spinout right through to securing the investment needed to commercialise their technology, hopefully bringing benefits to respiratory patients around the world.”
Nebu-Flow noted is chairman, John Pritchard, has more than 25 years of experience in the field, working in senior roles for GSK, AstraZeneca, 3M, and Philips.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here